A case-control study of gynecomastia in HIV-1-infected patients receiving HAART.
D000328:Adult; D000368:Aged; D000480:Alkynes; D000704:Analysis of Variance; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects* / Q000379:methods; D048588:Benzoxazines; D018791:CD4 Lymphocyte Count; D016022:Case-Control Studies; D003521:Cyclopropanes; D006177:Gynecomastia / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology* / Q000378:metabolism / Q000628:therapy; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D015497:HIV-1; D039682:HIV-Associated Lipodystrophy Syndrome / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009519:New York City / Q000453:epidemiology; D010078:Oxazines / Q000009:adverse effects; D012307:Risk Factors; D013739:Testosterone / Q000097:blood / Q000172:deficiency; D013997:Time Factors; D016896:Treatment Outcome
D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D010078:Oxazines; D013739:Testosterone; C098320:efavirenz